Cure Rates Hold Up Across Genetic Status For Vertex's Telaprevir
This article was originally published in The Pink Sheet Daily
Retrospective analyses of data from pivotal studies in both naïve and experienced patients showed patients from all three possible genotypes had substantial improvements with telaprevir, Vertex reported at EASL.
You may also be interested in...
Dual FDA Advisory Committee Reviews Shaping Up To Be A Showdown For Dueling Merck And Vertex Hepatitis C Drugs
Approval is widely assumed for both boceprevir and telaprevir, but there is still much to be discussed about the devilish details. Additional data coming out at European liver meeting should also be informative.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.